Sugi Predict
/ Targets
/ CDK9
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to CDK9 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) |
PHASE3 | COMPLETED |
| A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) |
PHASE3 | COMPLETED |
| Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients |
PHASE3 | RECRUITING |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) |
PHASE3 | RECRUITING |
| Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression |
PHASE2 | COMPLETED |
| CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy |
PHASE2 | COMPLETED |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia |
PHASE2 | COMPLETED |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) |
PHASE1/PHASE2 | RECRUITING |
| Palbociclib With Everolimus + Exemestane In BC |
PHASE1/PHASE2 | COMPLETED |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML |
PHASE1/PHASE2 | RECRUITING |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 |
PHASE2 | RECRUITING |
| Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer |
PHASE1/PHASE2 | RECRUITING |
| A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer |
PHASE1/PHASE2 | COMPLETED |
| BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors |
PHASE2 | WITHDRAWN |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. |
PHASE2 | COMPLETED |
| A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer |
PHASE1/PHASE2 | UNKNOWN |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma |
PHASE1 | COMPLETED |
| A Study of PRT2527 in Participants With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy |
PHASE1 | RECRUITING |
| Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy |
nan | COMPLETED |
| Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period |
nan | UNKNOWN |
| The SONImage Study |
nan | ACTIVE_NOT_RECRUITING |
| EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC) |
nan | RECRUITING |
| Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a CDK9 binder may also engage these)